Form 4: Madrigal Pharmaceuticals Director Paul Friedman Receives Equity Compensation Grant

Madrigal Pharmaceuticals, Inc. Director Paul A. Friedman reported the acquisition of restricted stock units and stock options as part of his compensation, aligning his interests with shareholders.

Summary

• Paul A. Friedman, a Director of Madrigal Pharmaceuticals, Inc. (MDGL), reported changes in his beneficial ownership of company securities.
• On June 20, 2025, Mr. Friedman was granted 715 shares of Common Stock in the form of restricted stock units (RSUs) at a price of $0.00 per share.
• These RSUs are scheduled to vest on the date of the Issuer's annual meeting of stockholders in 2026, contingent on Mr. Friedman's continued service.
• Additionally, on June 20, 2025, Mr. Friedman was granted 1,290 stock options with an exercise price of $285.73 per share, also at a transaction price of $0.00.
• These stock options will vest 100% on the date of the Issuer's annual meeting of stockholders in 2026, provided he continues to serve as a director until that date.
• Following these transactions, Mr. Friedman directly beneficially owns 187,164 shares of Common Stock and 1,290 stock options.
• He also indirectly beneficially owns 655,540 shares of Common Stock through SQN LLC, where he and his spouse are managing members.

Sentiment

Score: 7

Explanation: The sentiment is moderately positive as the equity grant aligns the director's interests with shareholders, indicating continued commitment and incentivizing long-term performance, which is a standard and healthy corporate governance practice.

Positives

• The grant of restricted stock units and stock options to a director aligns management's interests with those of shareholders, incentivizing long-term performance.
• The compensation structure encourages the director's continued service to the company.

Future Outlook

This filing does not contain forward-looking statements regarding the company's financial performance or strategic outlook, focusing solely on an insider's equity compensation.

Industry Context

The granting of equity compensation, such as restricted stock units and stock options, to directors is a standard practice across publicly traded companies, particularly in the biotechnology and pharmaceutical sectors, to attract and retain talent and align their interests with long-term shareholder value.

Related Party Transactions

• Paul A. Friedman indirectly beneficially owns 655,540 shares of Common Stock through SQN LLC, where he and his spouse are managing members. This indirect ownership is a disclosed related party interest.

Stakeholder Impact

• Shareholders: The equity grant aligns the director's financial interests with shareholder value creation, potentially leading to more focused long-term decision-making.
• Employees: No direct impact on general employees is indicated by this filing.

Next Steps

• The restricted stock units and stock options are expected to vest on the date of the Issuer's annual meeting of stockholders in 2026, subject to the director's continued service.

Key Dates

Keywords

Madrigal Pharmaceuticals, MDGL, SEC Form 4, Insider Transaction, Equity Grant, Restricted Stock Units, Stock Options, Director Compensation, Beneficial Ownership